Introduction

Pancreaticopleural fistula (PPF) is a type of internal fistula, wherein the pancreatic secretions drain directly into the pleural cavity. It can occur as a complication of acute and chronic pancreatitis or after a traumatic disruption of the pancreatic duct.[1] Its prevalence is estimated to be 0.4% in patients with pancreatitis. It accounts for less than 1% of all cases of pleural effusion.[2] It is seen more commonly in patients with chronic pancreatitis than acute pancreatitis.[3] Therapeutic options for PPF are limited. Endoscopic retrograde choangiopancreatography (ERCP) plays a role if a discrete leak is demonstrable.

We report two cases of PPF, which were successfully treated with ERCP and placement of a plastic stent in the main pancreatic duct.

Case Report

Case 1

A 53-year-old male, with a previous diagnosis of alcohol-related chronic pancreatitis since the last five years, presented to us with a sudden onset of progressive shortness of breath. He had a previous history of a pancreatic pseudoaneurysm, which was embolized. He also had a pancreatic pseudocyst, which was not treated because he was not symptomatic.

Investigations revealed a hemoglobin of 6.1 g/dl, serum amylase 341 IU/L (reference range: 5-100 IU/L), with normal renal and liver function tests. A chest x-ray showed a left opaque hemothorax, suggestive of pleural collection. Computed tomography (CT) angiography of the chest and abdomen showed a massive left pleural effusion and chronic calcific pancreatitis, but there was no evidence of any pseudoaneurysm [Figure 1]. Pleurocentesis was performed and one liter of hemorrhagic fluid was removed. A biochemical examination of the aspirated fluid revealed protein 3.9 g/dl and amylase 11705 IU/L. A provisional diagnosis of PPF was made and ERCP was planned. The patient had recurrence of respiratory distress and a chest x-ray showed refilling of the pleural effusion that necessitated insertion of an intercostal chest tube. About 2.8 liters of fluid was drained in 24 hours,
which resulted in symptomatic improvement and adequate expansion of the lung parenchyma. An ERCP pancreatogram showed that the main pancreatic duct was dilated, without any stricture or stone and leak of contrast from the distal body. A 7 F stent was placed in the pancreatic duct [Figure 2]. Chest drainage decreased to 200 ml in the next 24 hours and became nil after two days. The chest tube was removed after four days, after confirming lung expansion on a chest x-ray [Figure 3]. There was no reaccumulation of pleural effusion in the three-month follow-up.

**Case 2**
A 61-year-old male presented with pain in the abdomen and was found to have cholelithiasis and a cystic mass in the region of the tail of the pancreas. About 50 ml of fluid was aspirated under endoultrasound guidance. The analysis of fluid revealed amylase of 60668 IU/L. He remained asymptomatic for three to four months and again presented with pain in the abdomen and a repeat workup showed a cystic collection in the tail of the pancreas and a moderate left-sided pleural effusion. Diagnostic pleurocentesis was performed, which showed protein 5 g/dl and amylase 26240 IU/L. A CT scan of the chest and abdomen was done, which showed a moderate left pleural effusion, cholelithiasis, and a pseudocyst in the tail of pancreas, along with ductal changes of pancreatitis [Figure 4]. ERCP was done with the purpose of PD stenting, A pancreatogram revealed a leak from the tail into the pseudocyst and a 5 F stent was placed in the pancreatic duct [Figure 5]. A chest x-ray done after three days showed resolution of the pleural effusion [Figure 6]. There was no recurrence of pleural effusion at the two-month follow-up.

**Discussion**
Pleural effusion in pancreatic disease occurs due to two mechanisms. The first is reactionary pleural effusion due to pancreatitis, which is usually small and left-sided (may be bilateral). It is characterized by a normal amylase level (< 1000 U/L) and low protein concentration (< 3 g/dl). This type of effusion is seen in acute pancreatitis and resolves.
spontaneously, with recovery of the disease. The second type of pleural effusion in patients with pancreatitis is usually large, left-sided, recurrent, and has a high level of amylase (> 1000 U/L) and proteins (> 3 g/dl). This type of effusion is seen in both chronic and recurrent pancreatitis. In this type of effusion, fluid accumulates in the pleural cavity due to a fistulous communication between either a pancreatic duct or a pseudocyst and the pleura.[5]

The underlying mechanism for PPF is usually a leak from the pseudocyst, but a direct pancreatic duct leak also been reported. The fistulous tract passes either through the aortic or esophageal diaphragmatic orifices or directly, transdiaphragmatically. If pancreatic duct disruption develops posteriorly, the pancreatic secretions flow into the retroperitoneum and may dissect into the mediastinum through the aortic or esophageal hiatus and form a pleural fistula. Uncommonly a mediastinal pseudocyst ruptures into the pleural space and forms a PPF. If the disruption occurs anteriorly and is not walled off, a pancreatic-peritoneal fistula develops, which manifests as pancreatic ascites.[6]

The clinical features are often variable, but overall, pulmonary symptoms are more common than abdominal symptoms. According to Ali et al.,[7] the most common symptoms are due to pleural effusion, that is, dyspnea in 65%, cough in 27%, and chest pain in 23%. Abdominal pain has been reported in 29% of the cases. Our first case had a typical presentation of PPF, but in the second case, PPF was an incidental finding.

Clinically, a massive pleural effusion with a high fluid amylase level and increased protein concentration in a patient with pancreatitis suggests a diagnosis of PPF.[6,7] Other causes of high amylase in the pleural fluid are, acute pancreatitis, pneumonia, liver cirrhosis, pulmonary tuberculosis, esophageal perforation, female reproductive tract malignancy, lung cancer, metastatic carcinoma, lymphoma, and leukemia.

A direct demonstration of this fistulous communication is difficult. An ultrasound is not a good imaging modality, as the bowel loops interfere with the image quality.[8] A CT scan is very useful in determining the size of the effusion and also reveals changes of the pancreatitis. A CT scan may demonstrate the fistulous tract, especially if obtained immediately after an ERCP. Computed tomography has been done in most studies reporting PPFs, but it is able to demonstrate fistula only in 33-47% of the cases, because of limitation of resolution of the CT and the poorly enhancing walls of the fistula, which is usually masked within the pseudocysts.[7] Magnetic resonance cholangiopancreatography (MRCP) is considered the investigation of choice for suspected PPF with a sensitivity of 80%. It provides information about the pancreatic duct beyond the stricture. In addition, a small pseudocyst, peripancreatic collection, and the PPF can be seen. It is useful where ERCP fails, to give adequate information about the ductal anatomy.[9] Multiple pseudocysts or ascites limit the resolution of MRCP.[10] ERCP demonstrates a leak from the main pancreatic duct with a sensitivity of 46-78%. ERCP may not be useful in patients in whom the site of the ductal disruption is distal to the stricture. The main advantage of ERCP is its therapeutic ability apart from imaging. In our cases, diagnosis was possible with a chest x-ray and pleural fluid analysis in both the cases. A CT scan could not demonstrate the fistulous tract and ERCP demonstrated a leak from the main pancreatic duct in both the cases.

Therapeutic options for PPF include medical treatment, endoscopic management, and surgery. The aim of medical treatment is to reduce pancreatic exocrine secretions. Somatostatin analogs are most commonly used along with thoracentesis and/or tube thoracostomy, which encourage the apposition of pleural surfaces. Medical treatment is usually attempted for two to three weeks. Octreotide administration along with ERCP and stenting has been used for a longer period (2.5 to 6 months).[11] Octreotide is given in an initial dosage of 50 ug, administered subcutaneously three times a day, and the dose is titrated based upon the fistula.
output. The maximal dose employed is 250 μg, three times daily.\(^{[11,12]}\) It is reported that octreotide significantly reduces the fistula output and decreases the time to fistula closure.\(^{[12]}\) Measures like the prohibition of oral intake, nasogastric or nasojejunal tube insertion, and total parenteral nutrition used in the past are no longer necessary. The reported success rate of medical management is 30-60%.\(^{[13]}\) However, patients who fail medical treatment have higher rates of complications if they undergo surgery.

Endoscopic retrograde cholangiopancreatography has been used to treat PPF in cases where there is a leak from the main pancreatic duct without a proximal stricture. Therapeutic options at ERCP include endoscopic papillotomy, nasopancreatic tube placement, and placement of a stent in the main pancreatic duct.

Endoscopic papillotomy alone may help in fistula closure by producing a lower pressure gradient for drainage of pancreatic secretions.\(^{[11]}\) Insertion of a nasopancreatic tube has been used for one week, followed by placement of an endoprosthesis in the pancreatic duct, if the fistula persists.\(^{[6,14]}\) The advantage of a nasopancreatic tube, in contrast to stent placement, is that it allows the pancreaticogram to be obtained repeatedly, without further invasive procedures. It also allows application of low intermittent suction, which may potentially facilitate closure of a leak or fistula.\(^{[14]}\) However, the major drawbacks include the necessity for continued hospitalization and patient discomfort due to the presence of the tube in the nose.\(^{[14]}\) Stenting decompresses the duct and can bridge the site of ductal disruption. Fistulae, which arise from the head or body, are most suitable for bridging with a stent, however, it

![Figure 7: Proposed algorithm for treatment of PPF](Image)
may not be possible when the fistula arises from the tail of the pancreas and the stent may have to be placed close to the duct disruption.\[6,14\] Bridging pancreatic stents help to close the fistula rapidly by decreasing the ductal pressure and by abolition of the pancreatic pressure gradient. Either a 5 F or 7 F size of stents are used in a pancreatic duct.\[6,14\] The optimum duration of drainage for fistulae is unknown, but can vary from four to twelve weeks. In patients with a stricture, the stent may be changed sequentially from two to twelve months.\[6\] Assessment of the persistence of fistula can be done by repeating ERCP at six-week intervals and documenting the leak of the dye.\[11\] However, long-term use of a stent causes ductal changes that may persist even after its removal.\[13\] As data on the long-term consequence of stent placement is lacking, it is difficult to draw a definite conclusion.\[6\] A significant proportion of these patients may require surgery, particularly for persistent, recurrent fluid collections.\[16\] The issue of how long to continue with endoscopic treatment is still unresolved.\[12\]

In both reported cases, ERCP and stenting of the main pancreatic duct led to the complete resolution of PPF, despite the site of the leak being in the distal PD and the stent not bridging the leak. The probable reason for this was lack of proximal stricture or stone.

Surgery is usually considered in patients who fail conservative and endoscopic treatment.\[12,13\] Surgical treatment includes either pancreatic resection or enteropancreatic anastomosis to the site of pancreatic duct leakage or to the pseudocyst.\[11,12\] If there is an obstruction of the main pancreatic duct proximal to the fistula, surgical treatment is necessary to decompress the obstructed duct. Cystogastrostomy, cystojejunostomy, and distal and middle pancreatectomy are appropriate options in the setting of symptomatic pancreatic pseudocysts or pancreatic duct obstruction.\[11,13\]

In a review of 63 patients, King et al., reported that medical therapy was successful only in 31% of the cases, whereas, surgical therapy was likely to succeed more than three times (94%), when applied as either an initial strategy or after failed medical management.\[13\] Complications were noted in 16% of the patients and death occurred in 3%. It was also noted that 70% of the complications that followed surgical intervention were seen in patients in whom conversion from medical to operative therapy was required. Most of the patients were initially treated with medical therapy (87%) and it was deemed to have failed after an average period of 35 ± 5 days. The total duration of therapy for patients in whom surgery was required after attempted medical management was 40 ± 6 days, which was greater than the ‘surgery-alone’ cohort.\[13\] These observations strongly advocate that surgery should be the first line of treatment, if expertise is available.

Conclusion
Pancreaticopleural fistula should be considered as a diagnosis in cases of pleural effusion, in patients with chronic or recurrent pancreatitis. Pleural fluid amylase estimation is sufficient to establish the diagnosis. CT and/or MRCP are the main imaging modalities to demonstrate PPF. Treatment options are medical, ERCP, and surgery. The treatment algorithm for PPF is not well-defined. We propose a treatment algorithm in patients with PPF, which takes into account the general condition of the patient, the pancreatic ductal anomaly, and the response to treatment [Figure 7].

References


Source of Support: Nil, Conflict of Interest: None declared.